Clearside Biomedical, Inc. financial data

Symbol
CLSD on Nasdaq
Industry
Pharmaceutical Preparations
Location
900 North Point Parkway, Suite 200, Alpharetta, Georgia
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 10, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 558 % -32.6%
Debt-to-equity -366 % -267%
Return On Equity 252 %
Return On Assets -94.7 % -24.8%
Operating Margin -301 % +90.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 74.7 M shares +21.8%
Common Stock, Shares, Outstanding 74.7 M shares +21.8%
Entity Public Float 64 M USD -20%
Common Stock, Value, Issued 74 K USD +21.3%
Weighted Average Number of Shares Outstanding, Basic 69.9 M shares +14.2%
Weighted Average Number of Shares Outstanding, Diluted 69.9 M shares +14.2%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 8.45 M USD +759%
Research and Development Expense 22 M USD +12.6%
General and Administrative Expense 11.5 M USD +0.56%
Operating Income (Loss) -25.4 M USD +15.8%
Net Income (Loss) Attributable to Parent -35 M USD -1.11%
Earnings Per Share, Basic -0.55 USD/shares +3.51%
Earnings Per Share, Diluted -0.55 USD/shares +3.51%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.4 M USD -14.6%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Other Assets, Current 193 K USD -50%
Assets, Current 36.1 M USD -15.2%
Property, Plant and Equipment, Net 3.19 M USD +207%
Operating Lease, Right-of-Use Asset 803 K USD -24%
Other Assets, Noncurrent 30 K USD 0%
Assets 40.1 M USD -10.2%
Accounts Payable, Current 1.36 M USD -14.5%
Employee-related Liabilities, Current 592 K USD +3.68%
Accrued Liabilities, Current 4.07 M USD +47.8%
Liabilities, Current 5.95 M USD +19.4%
Operating Lease, Liability, Noncurrent 572 K USD -34%
Other Liabilities, Noncurrent 480 K USD
Liabilities 62 M USD +47.5%
Retained Earnings (Accumulated Deficit) -333 M USD -11.7%
Stockholders' Equity Attributable to Parent -21.8 M USD -908%
Liabilities and Equity 40.1 M USD -10.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.85 M USD -8.8%
Net Cash Provided by (Used in) Financing Activities 14.3 M USD +4220%
Net Cash Provided by (Used in) Investing Activities -57 K USD +50.4%
Common Stock, Shares Authorized 200 M shares 0%
Common Stock, Shares, Issued 74.7 M shares +21.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.44 M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 84 M USD +14%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Operating Lease, Liability 1.01 M USD -21.2%
Depreciation 28 K USD +86.7%
Payments to Acquire Property, Plant, and Equipment 57 K USD -50.4%
Property, Plant and Equipment, Gross 4.14 M USD +117%
Operating Lease, Liability, Current 367 K USD +3.09%
Deferred Tax Assets, Operating Loss Carryforwards 52.7 M USD +4.76%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 7.52 M USD 0%
Operating Lease, Payments 362 K USD +6.79%
Additional Paid in Capital 311 M USD +3.48%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%